The Latest Analyst Ratings for Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
10 Analysts Have This to Say About Merus
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
AstraZeneca’s Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson’s Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Where Merus Stands With Analysts
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Merus N.V. Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the
Expert Ratings for Merus
Merus (NASDAQ:MRUS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Merus N.V. Announces Zenocutuzumab Granted Second Breakthrough Therapy Designation By The U.S. Food & Drug Administration
– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology
Analyst Expectations for Merus’s Future
Merus (NASDAQ:MRUS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Merus Appoints Life Sciences Strategic And Financial Industry Veteran Greg Perry As Chief Financial Officer
Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the
Where Merus Stands With Analysts
Merus (NASDAQ:MRUS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…